Companies Dominating the Obstructive Laryngitis Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Reckitt Benckiser Group PLC
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- AstraZeneca
- Novartis Pharmaceuticals Corporation
- Walgreen Co.
- Prestige Consumer Healthcare Inc.
- Perrigo Company plc
Browse Key Market Insights with Data Illustration:
In the News
- October, 2022-Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC® ODT (rimegepant), an inventive migraine treatment authorized for the acute treatment as well as the prevention of episodic migraine in adults, was acquired by Pfizer Inc., it was reported.
- July 2020 - The FDA in the United States has authorized AstraZeneca's Breztri Aerosphere as a maintenance medication for patients with chronic obstructive pulmonary disease (COPD).
- Breztri Aerosphere, formerly known as PT010, is an inhalation medication that contains three active ingredients: the corticosteroid budesonide, the long-acting beta-2 agonist formoterol fumarate, and the long-acting muscarinic antagonist glycopyrronium.
